Candel Therapeutics, Inc.(CADL)
Biotechnology
Oncology Biotech
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | Manning Paul B Director | Purchase | +550,458 | +24.87%2,763,527 | $5.45 | $2,999,996 | View SEC filing | |
| 2025-07-30 | Nichols William Garrett Chief Medical Officer | Sale | -937 | -1.75%52,493 | $6.98 | $6,540 | View SEC filing | |
| 2025-07-02 | Nichols William Garrett Chief Medical Officer | Sale | -781 | -1.47%52,493 | $5.04 | $3,936 | View SEC filing | |
| 2025-03-20 | Nichols William Garrett Chief Medical Officer | Sale | -45,316 | -46.33%52,493 | $8.76 | $396,995 | View SEC filing | |
| 2025-03-20 | Barone Francesca Chief Scientific Officer | Sale | -32,146 | -24.98%96,527 | $8.76 | $281,673 | View SEC filing | |
| 2025-03-20 | Tak Paul Peter Chief Executive Officer | Sale | -26,172 | -10.39%225,740 | $8.77 | $229,624 | View SEC filing | |
| 2025-03-20 | Tyagarajan Seshu Chief Technology Officer | Sale | -31,278 | -26.78%85,512 | $8.82 | $275,947 | View SEC filing | |
| 2025-03-19 | Tyagarajan Seshu Chief Technology Officer | Sale | -31,278 | -26.78%85,512 | $8.82 | $275,947 | View SEC filing | |
| 2025-03-19 | Schoch Charles See Remarks | Sale | -5,000 | -11.62%38,038 | $8.83 | $44,169 | View SEC filing | |
| 2025-01-17 | Tyagarajan Seshu Chief Technology Officer | Sale | -14,322 | -12.89%96,790 | $7.22 | $103,476 | View SEC filing | |
| 2025-01-17 | Barone Francesca Chief Scientific Officer | Sale | -13,534 | -10.90%110,673 | $7.22 | $97,783 | View SEC filing | |
| 2025-01-17 | Schoch Charles See Remarks | Sale | -9,511 | -18.10%43,038 | $7.23 | $68,717 | View SEC filing | |
| 2025-01-17 | Tak Paul Peter Chief Executive Officer | Sale | -21,704 | -7.93%251,912 | $7.22 | $156,811 | View SEC filing | |
| 2025-01-17 | Nichols William Garrett Chief Medical Officer | Sale | -10,428 | -11.62%79,320 | $7.23 | $75,342 | View SEC filing | |
| 2025-01-10 | Barone Francesca Chief Scientific Officer | Sale | -13,673 | -9.92%124,207 | $8.22 | $112,367 | View SEC filing | |
| 2025-01-10 | Schoch Charles See Remarks | Sale | -9,971 | -15.95%52,549 | $8.22 | $81,944 | View SEC filing | |
| 2025-01-10 | Tak Paul Peter Chief Executive Officer | Sale | -21,172 | -7.18%273,616 | $8.22 | $173,996 | View SEC filing | |
| 2025-01-10 | Tyagarajan Seshu Chief Technology Officer | Sale | -14,545 | -11.58%111,112 | $8.22 | $119,534 | View SEC filing | |
| 2025-01-10 | Nichols William Garrett Chief Medical Officer | Sale | -10,799 | -10.74%89,748 | $8.22 | $88,749 | View SEC filing | |
| 2024-12-18 | Manning Paul B Director | Purchase | +1,250,000 | +104.50%2,446,158 | $6.00 | $7,500,000 | View SEC filing | |
| 2024-12-03 | Tyagarajan Seshu Chief Technology Officer | Sale | -20,392 | -13.96%125,657 | $4.56 | $92,898 | View SEC filing | |
| 2024-12-03 | Tak Paul Peter Chief Executive Officer | Sale | -48,847 | -14.21%294,788 | $4.56 | $222,527 | View SEC filing | |
| 2024-12-03 | Nichols William Garrett Chief Medical Officer | Sale | -13,935 | -12.17%100,547 | $4.56 | $63,482 | View SEC filing | |
| 2024-12-03 | Barone Francesca Chief Scientific Officer | Sale | -22,081 | -13.80%137,880 | $4.56 | $100,592 | View SEC filing | |
| 2024-10-15 | Aguilar Laura K. 10% Owner | Sale | -40,412 | -4.21%919,461 | $6.03 | $243,834 | View SEC filing |
1-25 of 50